Regulation of Molecular Targets in Osteosarcoma Treatment

Betul Celik1,2, Kader Cicek1,2, Andrés Felipe Leal2

  • 1Department of Biological Science, University of Delaware, Newark, DE 19716, USA.

Insights

RNA interference offers a promising new avenue for treating osteosarcoma, particularly in recurrent or metastatic cases. This approach utilizes small interfering RNAs to target and silence specific genes, potentially halting tumor growth and spread.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biotechnology

Background:

  • Osteosarcoma is a common bone cancer in young adults, with limited treatment success in advanced stages.
  • Current chemotherapy shows poor efficacy for recurrent and metastatic osteosarcoma, necessitating novel therapeutic strategies.
  • RNA interference (RNAi) presents a promising gene-silencing approach for cancer therapy.

Purpose of the Study:

  • To review potential therapeutic targets for RNA interference (RNAi) in osteosarcoma treatment.
  • To explore the application of small interfering RNAs (siRNAs) for targeting patient-specific mutations in osteosarcoma.
  • To highlight the potential of siRNA-based therapies for addressing unmet needs in osteosarcoma relapse.

Main Methods:

  • Review of current literature on RNA interference technologies in cancer therapy.
  • Discussion of gene targets and tissue-specific promoters for osteosarcoma treatment.
  • Evaluation of lentiviral vectors for efficient siRNA delivery and long-term gene regulation.

Main Results:

  • Silencing overexpressed genes via RNAi can reduce tumor cell invasiveness, proliferation, and induce apoptosis.
  • RNAi offers a personalized medicine approach by targeting unique mutations in individual cancer cells.
  • Lentiviral vectors facilitate effective cytoplasmic delivery and genomic integration of therapeutic siRNAs.

Conclusions:

  • RNA interference, particularly using small interfering RNAs, is a promising therapeutic strategy for osteosarcoma.
  • Targeting patient-specific genes with RNAi can overcome challenges in treating recurrent and metastatic disease.
  • Further research into specific targets and delivery systems is crucial for clinical application of RNAi in osteosarcoma.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.7K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.2K